cefuroxime ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, cefalosporanic acid derivatives 565 55268-75-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cefuroxime
  • biofuroxim
  • cefaloxime
  • cefasyn
  • cefuroxim
  • cefuroxime acid
  • cephuroxime
  • cefuroxime sodium
  • cefuroxime sodium salt
Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS.
  • Molecular weight: 424.38
  • Formula: C16H16N4O8S
  • CLOGP: 0.44
  • LIPINSKI: 1
  • HAC: 12
  • HDO: 3
  • TPSA: 173.76
  • ALOGS: -3.17
  • ROTB: 8

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.50 g O
3 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 89 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 96 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 39.35 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 32 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.15 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.20 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Oct. 19, 1983 FDA COVIS INJECTABLES

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 253.09 12.86 127 17971 23506 63447418
Anaphylactic reaction 241.28 12.86 178 17920 65922 63405002
Macular oedema 145.60 12.86 51 18047 3826 63467098
Retinal detachment 141.44 12.86 56 18042 5913 63465011
Corneal oedema 111.03 12.86 33 18065 1460 63469464
Bronchospasm 87.57 12.86 57 18041 17223 63453701
Patent ductus arteriosus 87.35 12.86 36 18062 4214 63466710
Type IV hypersensitivity reaction 85.87 12.86 32 18066 2866 63468058
Foetal exposure during pregnancy 83.99 12.86 71 18027 31891 63439033
Premature baby 82.74 12.86 59 18039 20676 63450248
Corneal opacity 80.38 12.86 22 18076 721 63470203
Exposure during pregnancy 78.69 12.86 151 17947 155396 63315528
Drug reaction with eosinophilia and systemic symptoms 74.55 12.86 68 18030 33768 63437156
Retinal oedema 67.75 12.86 19 18079 682 63470242
Anterior chamber inflammation 66.43 12.86 16 18082 311 63470613
Type I hypersensitivity 64.14 12.86 26 18072 2916 63468008
Rash maculo-papular 62.38 12.86 60 18038 31836 63439088
Endophthalmitis 59.14 12.86 26 18072 3566 63467358
Joint swelling 53.01 12.86 14 18084 327652 63143272
Parophthalmia 51.45 12.86 13 18085 310 63470614
Alopecia 49.92 12.86 17 18081 337519 63133405
Retinal toxicity 48.74 12.86 17 18081 1258 63469666
Premature delivery 48.28 12.86 51 18047 30230 63440694
Accidental overdose 47.77 12.86 45 18053 23264 63447660
Dysbiosis 46.19 12.86 15 18083 891 63470033
Cataract operation complication 45.28 12.86 10 18088 130 63470794
Premature rupture of membranes 45.24 12.86 24 18074 4969 63465955
Cystoid macular oedema 45.24 12.86 17 18081 1558 63469366
Low birth weight baby 44.89 12.86 27 18071 7102 63463822
Systemic lupus erythematosus 44.84 12.86 4 18094 208914 63262010
Rheumatoid arthritis 44.71 12.86 9 18089 253810 63217114
Angioedema 43.96 12.86 61 18037 47904 63423020
Cross sensitivity reaction 43.36 12.86 18 18080 2144 63468780
Retinopathy 43.17 12.86 20 18078 3099 63467825
Corneal deposits 42.59 12.86 11 18087 287 63470637
Arthropathy 42.03 12.86 8 18090 234784 63236140
Clostridium difficile infection 41.78 12.86 47 18051 29875 63441049
Drug interaction 41.07 12.86 151 17947 228980 63241944
Resuscitation 38.97 12.86 14 18084 1130 63469794
Swelling 38.79 12.86 15 18083 275363 63195561
Infusion related reaction 38.73 12.86 11 18087 245510 63225414
Visual acuity reduced 37.01 12.86 38 18060 21788 63449136
Congenital tricuspid valve incompetence 36.97 12.86 8 18090 94 63470830
Circulatory collapse 36.85 12.86 38 18060 21900 63449024
Kounis syndrome 36.72 12.86 15 18083 1715 63469209
Multiple organ dysfunction syndrome 36.20 12.86 61 18037 56691 63414233
Toxic epidermal necrolysis 35.72 12.86 40 18058 25294 63445630
Hypotension 35.66 12.86 163 17935 272441 63198483
Meningitis candida 35.24 12.86 7 18091 52 63470872
Treatment failure 35.16 12.86 7 18091 199036 63271888
Congenital pulmonary hypertension 34.67 12.86 7 18091 57 63470867
Pneumonia mycoplasmal 34.08 12.86 12 18086 913 63470011
Therapeutic product effect decreased 33.70 12.86 7 18091 193180 63277744
Conjunctival oedema 33.28 12.86 11 18087 691 63470233
Airway peak pressure increased 33.14 12.86 9 18089 286 63470638
Toxic anterior segment syndrome 33.03 12.86 14 18084 1757 63469167
Trimethylaminuria 32.76 12.86 8 18090 165 63470759
Lip swelling 32.27 12.86 42 18056 31021 63439903
Contraindicated product administered 32.09 12.86 11 18087 217637 63253287
Fatigue 31.79 12.86 138 17960 887890 62583034
Drug intolerance 31.64 12.86 25 18073 308636 63162288
Toxoplasmosis 31.63 12.86 13 18085 1510 63469414
Foetal non-stress test abnormal 31.61 12.86 6 18092 34 63470890
Musculoskeletal stiffness 31.56 12.86 7 18091 184611 63286313
Face oedema 30.38 12.86 33 18065 20179 63450745
Cardiac massage 29.70 12.86 5 18093 12 63470912
Stevens-Johnson syndrome 29.52 12.86 36 18062 24914 63446010
Anterior chamber fibrin 29.38 12.86 6 18092 52 63470872
Cardiovascular insufficiency 28.91 12.86 12 18086 1429 63469495
Urticaria 28.62 12.86 108 17990 165694 63305230
Pseudomembranous colitis 28.31 12.86 15 18083 3097 63467827
Product monitoring error 28.17 12.86 17 18081 4499 63466425
Tachypnoea 27.32 12.86 29 18069 17273 63453651
Pain 27.13 12.86 114 17984 740514 62730410
Pericarditis 26.96 12.86 3 18095 131576 63339348
Joint hyperextension 26.80 12.86 8 18090 359 63470565
Blood pressure decreased 26.74 12.86 58 18040 64964 63405960
Antidiuretic hormone abnormality 26.70 12.86 5 18093 26 63470898
Sepsis syndrome 26.45 12.86 10 18088 932 63469992
Drug hypersensitivity 26.39 12.86 165 17933 310522 63160402
Nephritis allergic 25.98 12.86 7 18091 216 63470708
Boutonneuse fever 25.88 12.86 4 18094 4 63470920
Vulval cancer metastatic 25.88 12.86 4 18094 4 63470920
Macular ischaemia 25.56 12.86 5 18093 34 63470890
Linear IgA disease 25.51 12.86 11 18087 1440 63469484
Oesophageal spasm 25.47 12.86 14 18084 3109 63467815
Discomfort 25.47 12.86 8 18090 167366 63303558
Staphylococcal sepsis 25.44 12.86 20 18078 8108 63462816
Ocular toxicity 25.36 12.86 9 18089 701 63470223
Hypopyon 25.09 12.86 9 18089 723 63470201
Clostridium difficile colitis 24.85 12.86 30 18068 20539 63450385
Arthralgia 23.86 12.86 83 18015 569627 62901297
Oliguria 23.45 12.86 20 18078 9081 63461843
Oesophageal pain 23.26 12.86 14 18084 3687 63467237
Renal failure 23.15 12.86 80 18018 117572 63353352
Toxic skin eruption 22.88 12.86 23 18075 12862 63458062
Weight increased 22.16 12.86 25 18073 260767 63210157
Jaundice 22.14 12.86 34 18064 29217 63441707
Tachycardia 22.09 12.86 79 18019 118077 63352847
Restlessness 21.97 12.86 34 18064 29419 63441505
Hyperleukocytosis 21.89 12.86 8 18090 678 63470246
Erythema 21.41 12.86 103 17995 175648 63295276
Pyroglutamate increased 21.27 12.86 7 18091 434 63470490
Wound 21.20 12.86 10 18088 163253 63307671
Abdominal discomfort 21.06 12.86 37 18061 320848 63150076
Bulimia nervosa 20.77 12.86 7 18091 467 63470457
Foetal anaemia 20.77 12.86 5 18093 97 63470827
Nosocomial infection 20.64 12.86 10 18088 1711 63469213
Merycism 19.98 12.86 6 18092 275 63470649
Product preparation issue 19.87 12.86 9 18089 1323 63469601
Vanishing twin syndrome 19.80 12.86 5 18093 119 63470805
Sepsis 19.57 12.86 91 18007 153032 63317892
Delayed delivery 19.35 12.86 4 18094 37 63470887
Idiopathic angioedema 19.26 12.86 4 18094 38 63470886
Natural killer cell count decreased 19.07 12.86 4 18094 40 63470884
Hydronephrosis 18.87 12.86 19 18079 10643 63460281
Colitis ischaemic 18.80 12.86 19 18079 10689 63460235
Acute kidney injury 18.79 12.86 134 17964 263281 63207643
Exophthalmos 18.76 12.86 9 18089 1507 63469417
Cutaneous vasculitis 18.76 12.86 14 18084 5255 63465669
Hepatic enzyme increased 18.76 12.86 18 18080 202310 63268614
Coma blister 18.53 12.86 5 18093 155 63470769
Tinnitus 18.48 12.86 35 18063 35593 63435331
Retroplacental haematoma 18.41 12.86 5 18093 159 63470765
Pyelonephritis 18.40 12.86 24 18074 17754 63453170
Serous retinal detachment 18.40 12.86 6 18092 361 63470563
Anaphylactoid reaction 18.17 12.86 12 18086 3711 63467213
Maculopathy 18.06 12.86 10 18088 2252 63468672
Eye inflammation 18.00 12.86 14 18084 5585 63465339
Intentional product use issue 17.93 12.86 7 18091 127885 63343039
Mediastinal effusion 17.71 12.86 4 18094 58 63470866
Moraxella infection 17.24 12.86 6 18092 441 63470483
Retinal infarction 17.22 12.86 4 18094 66 63470858
Hepatitis toxic 17.14 12.86 11 18087 3242 63467682
Pneumonia 17.06 12.86 202 17896 456565 63014359
Pupillary block 16.67 12.86 3 18095 12 63470912
Congenital lymphoedema 16.67 12.86 3 18095 12 63470912
Dermatitis allergic 16.54 12.86 21 18077 15127 63455797
Delivery 16.37 12.86 8 18090 1395 63469529
Bradycardia 16.36 12.86 52 18046 73175 63397749
Cerebral mass effect 16.31 12.86 7 18091 906 63470018
Anaemia of malignant disease 16.19 12.86 6 18092 529 63470395
Deafness bilateral 16.16 12.86 8 18090 1434 63469490
Coagulation time prolonged 16.13 12.86 8 18090 1440 63469484
Stenosis 16.10 12.86 8 18090 1446 63469478
Neonatal respiratory distress syndrome 16.02 12.86 10 18088 2808 63468116
Lower respiratory tract infection 15.84 12.86 9 18089 132298 63338626
Toxicity to various agents 15.78 12.86 29 18069 247221 63223703
Vitreous disorder 15.69 12.86 4 18094 99 63470825
Live birth 15.61 12.86 27 18071 25603 63445321
Acinetobacter infection 15.45 12.86 8 18090 1575 63469349
Lip oedema 15.27 12.86 11 18087 3913 63467011
B-lymphocyte count increased 15.02 12.86 4 18094 118 63470806
Retinal disorder 14.96 12.86 8 18090 1682 63469242
Blood creatinine increased 14.95 12.86 57 18041 87787 63383137
Gestational diabetes 14.93 12.86 15 18083 8381 63462543
Intermittent positive pressure breathing 14.91 12.86 3 18095 24 63470900
Cardiac arrest 14.90 12.86 59 18039 92486 63378438
Tubulointerstitial nephritis 14.88 12.86 23 18075 19880 63451044
Hypersensitivity vasculitis 14.80 12.86 11 18087 4101 63466823
Urticaria contact 14.80 12.86 3 18095 25 63470899
Cyanosis 14.71 12.86 21 18077 16914 63454010
Shock 14.66 12.86 25 18073 23438 63447486
Spinal muscular atrophy 14.59 12.86 3 18095 27 63470897
Abortion late 14.50 12.86 4 18094 135 63470789
Nasopharyngitis 14.36 12.86 32 18066 254225 63216699
HER2 positive breast cancer 14.32 12.86 5 18093 371 63470553
Cholestatic liver injury 14.18 12.86 9 18089 2601 63468323
Hepatosplenomegaly 14.17 12.86 9 18089 2605 63468319
Gait disturbance 14.04 12.86 19 18079 183159 63287765
Lymphoedema 14.04 12.86 17 18081 11675 63459249
Brain compression 13.90 12.86 5 18093 405 63470519
Product prescribing error 13.85 12.86 26 18072 26263 63444661
Cogwheel rigidity 13.82 12.86 8 18090 1962 63468962
Enanthema 13.71 12.86 5 18093 421 63470503
Sinobronchitis 13.68 12.86 4 18094 167 63470757
Hypotonia 13.67 12.86 15 18083 9270 63461654
Disturbance in attention 13.40 12.86 32 18066 38157 63432767
Fall 13.33 12.86 62 18036 392272 63078652
Pelvic fluid collection 13.33 12.86 6 18092 870 63470054
Hallucination 13.24 12.86 40 18058 54777 63416147
Normal newborn 13.20 12.86 14 18084 8327 63462597
Nail avulsion 13.12 12.86 4 18094 193 63470731
Paranasal sinus inflammation 12.98 12.86 5 18093 490 63470434
Intraocular pressure increased 12.96 12.86 12 18086 6066 63464858
Metabolic acidosis 12.94 12.86 35 18063 45034 63425890
Arteriospasm coronary 12.93 12.86 10 18088 3958 63466966

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Type IV hypersensitivity reaction 162.34 14.92 48 14788 1386 34940709
Anaphylactic reaction 139.40 14.92 113 14723 32188 34909907
Anaphylactic shock 129.54 14.92 82 14754 15859 34926236
Lung consolidation 120.29 14.92 56 14780 5880 34936215
Soft tissue mass 89.23 14.92 28 14808 991 34941104
Multimorbidity 87.17 14.92 27 14809 915 34941180
Rash maculo-papular 83.50 14.92 80 14756 28371 34913724
Oesophageal perforation 80.76 14.92 27 14809 1172 34940923
Retinal infarction 79.84 14.92 17 14819 118 34941977
Retinal toxicity 78.38 14.92 21 14815 419 34941676
Macular oedema 76.64 14.92 33 14803 2881 34939214
Spinal muscular atrophy 71.01 14.92 19 14817 377 34941718
Pyrexia 70.30 14.92 303 14533 332710 34609385
Superinfection 67.81 14.92 29 14807 2490 34939605
Drug reaction with eosinophilia and systemic symptoms 66.65 14.92 76 14760 32936 34909159
Inflammatory marker increased 65.08 14.92 35 14801 4993 34937102
Resuscitation 64.51 14.92 24 14812 1429 34940666
Pneumococcal sepsis 62.53 14.92 22 14814 1115 34940980
Macular detachment 60.12 14.92 13 14823 98 34941997
Endophthalmitis 58.62 14.92 29 14807 3479 34938616
Transplant failure 58.27 14.92 29 14807 3524 34938571
Stoma closure 57.75 14.92 15 14821 264 34941831
Retinal detachment 57.39 14.92 33 14803 5358 34936737
Ocular toxicity 55.15 14.92 14 14822 224 34941871
Toxic epidermal necrolysis 54.49 14.92 56 14780 21590 34920505
Corneal oedema 51.63 14.92 20 14816 1331 34940764
Motor neurone disease 48.60 14.92 15 14821 502 34941593
Lymphadenectomy 48.41 14.92 14 14822 373 34941722
Rales 47.79 14.92 37 14799 9846 34932249
Ischaemic cerebral infarction 46.02 14.92 18 14818 1229 34940866
Retinal oedema 45.27 14.92 15 14821 633 34941462
Increased bronchial secretion 45.23 14.92 20 14816 1861 34940234
Bronchial disorder 43.96 14.92 18 14818 1385 34940710
Sputum increased 43.83 14.92 21 14815 2349 34939746
Anticoagulation drug level above therapeutic 42.98 14.92 20 14816 2096 34939999
Clostridium difficile colitis 41.96 14.92 42 14794 15688 34926407
Immunosuppressant drug level increased 41.47 14.92 28 14808 6027 34936068
Lower respiratory tract infection bacterial 40.69 14.92 13 14823 488 34941607
Injury 40.68 14.92 47 14789 20640 34921455
Respiratory tract infection bacterial 39.82 14.92 18 14818 1764 34940331
Metabolic disorder 39.77 14.92 24 14812 4259 34937836
Bronchospasm 38.93 14.92 34 14802 10697 34931398
Oesophageal carcinoma 38.93 14.92 32 14804 9272 34932823
Lack of spontaneous speech 38.72 14.92 8 14828 47 34942048
Disease complication 38.10 14.92 20 14816 2716 34939379
Chest X-ray abnormal 36.64 14.92 23 14813 4375 34937720
Tachypnoea 36.60 14.92 42 14794 18310 34923785
Pathogen resistance 36.34 14.92 31 14805 9451 34932644
Death 35.00 14.92 73 14763 397976 34544119
Foetal exposure during pregnancy 34.91 14.92 60 14776 38041 34904054
Pulmonary vasculitis 34.51 14.92 12 14824 587 34941508
Intestinal intraepithelial lymphocytes increased 34.51 14.92 9 14827 161 34941934
Clostridium difficile infection 33.95 14.92 41 14795 18857 34923238
Kounis syndrome 33.91 14.92 18 14818 2500 34939595
Small for dates baby 33.89 14.92 21 14815 3906 34938189
Congenital pneumonia 33.80 14.92 8 14828 94 34942001
Intestinal ischaemia 33.01 14.92 27 14809 7767 34934328
Renal injury 31.92 14.92 31 14805 11164 34930931
Escherichia infection 31.69 14.92 27 14809 8218 34933877
Cryptitis 31.59 14.92 9 14827 227 34941868
Nervous system neoplasm 30.32 14.92 8 14828 150 34941945
Myocardial ischaemia 30.03 14.92 37 14799 17371 34924724
Neuritis 29.32 14.92 12 14824 922 34941173
Motor dysfunction 29.21 14.92 24 14812 6950 34935145
Inflammation 29.18 14.92 47 14789 28248 34913847
Biopsy 29.08 14.92 9 14827 304 34941791
Microvillous inclusion disease 28.46 14.92 8 14828 192 34941903
Haemoptysis 28.05 14.92 52 14784 34954 34907141
Brain injury 27.54 14.92 22 14814 6120 34935975
Pneumonia 27.00 14.92 253 14583 362374 34579721
Apoptosis 26.67 14.92 9 14827 402 34941693
Drug abuse 26.46 14.92 5 14831 99091 34843004
Probiotic therapy 26.45 14.92 7 14829 133 34941962
Fear 26.17 14.92 27 14809 10449 34931646
Maculopathy 25.82 14.92 11 14825 935 34941160
Renal graft infection 25.49 14.92 8 14828 283 34941812
Cardiomegaly 25.33 14.92 32 14804 15406 34926689
Atelectasis 24.83 14.92 34 14802 17693 34924402
Scoliosis 24.26 14.92 15 14821 2778 34939317
Visual acuity reduced 24.19 14.92 32 14804 16117 34925978
Dysphagia 23.63 14.92 69 14767 62312 34879783
Rotavirus infection 22.90 14.92 8 14828 397 34941698
Acute hepatic failure 22.81 14.92 29 14807 14045 34928050
Fluid intake reduced 22.71 14.92 16 14820 3685 34938410
Demyelination 22.31 14.92 15 14821 3206 34938889
Acute pulmonary oedema 22.19 14.92 21 14815 7322 34934773
Ascites 22.13 14.92 56 14780 46515 34895580
Acute generalised exanthematous pustulosis 21.67 14.92 20 14816 6756 34935339
Platelet count decreased 21.54 14.92 12 14824 119705 34822390
Product dose omission issue 21.54 14.92 12 14824 119699 34822396
Fibrinolysis increased 21.28 14.92 4 14832 13 34942082
Cerebral ischaemia 20.88 14.92 19 14817 6303 34935792
Atheroembolism 20.52 14.92 7 14829 323 34941772
Nosocomial infection 20.36 14.92 10 14826 1181 34940914
Labelled drug-drug interaction medication error 19.94 14.92 28 14808 14911 34927184
Systemic infection 19.89 14.92 17 14819 5195 34936900
Productive cough 19.59 14.92 47 14789 37766 34904329
Shock 19.47 14.92 36 14800 24143 34917952
Respiratory symptom 19.12 14.92 11 14825 1786 34940309
Circulatory collapse 19.09 14.92 33 14803 21005 34921090
Fatigue 18.95 14.92 87 14749 370566 34571529
Weight increased 18.75 14.92 8 14828 93025 34849070
Erythema 18.74 14.92 81 14755 88699 34853396
Escherichia urinary tract infection 18.73 14.92 14 14822 3532 34938563
Genitourinary tract infection 18.42 14.92 5 14831 105 34941990
Mechanical ventilation 18.19 14.92 11 14825 1959 34940136
Urticaria 18.14 14.92 63 14773 62314 34879781
Pneumococcal infection 18.05 14.92 7 14829 467 34941628
Mastocytosis 17.97 14.92 4 14832 35 34942060
Lip ulceration 17.92 14.92 8 14828 761 34941334
Retinopathy 17.71 14.92 11 14825 2053 34940042
Blood pressure decreased 17.64 14.92 55 14781 51460 34890635
Dyspnoea 17.58 14.92 240 14596 376542 34565553
Bronchopneumopathy 17.53 14.92 7 14829 505 34941590
Patent ductus arteriosus 17.18 14.92 13 14823 3341 34938754
Malignant neoplasm progression 17.07 14.92 8 14828 88038 34854057
Pseudomembranous colitis 16.98 14.92 12 14824 2779 34939316
Venous thrombosis 16.91 14.92 13 14823 3422 34938673
Foetal growth restriction 16.89 14.92 14 14822 4103 34937992
Lymphangitis 16.86 14.92 7 14829 558 34941537
Serratia infection 16.79 14.92 8 14828 884 34941211
Optic atrophy 16.60 14.92 8 14828 906 34941189
Insomnia 16.52 14.92 12 14824 103895 34838200
Normochromic normocytic anaemia 16.39 14.92 14 14822 4273 34937822
Multiple organ dysfunction syndrome 16.26 14.92 70 14766 76496 34865599
Retinal haemorrhage 16.24 14.92 15 14821 5074 34937021
Cross sensitivity reaction 16.08 14.92 9 14827 1388 34940707
Endotracheal intubation 15.97 14.92 12 14824 3053 34939042
Arthralgia 15.89 14.92 30 14806 170011 34772084
Acquired haemophilia 15.84 14.92 8 14828 1002 34941093
Pneumonectomy 15.70 14.92 4 14832 65 34942030
Vesicoureteric reflux 15.57 14.92 5 14831 191 34941904
Rhinalgia 15.53 14.92 8 14828 1045 34941050
Haemorrhoids thrombosed 15.32 14.92 5 14831 201 34941894
Product preparation issue 15.31 14.92 6 14830 412 34941683
Feeling abnormal 15.24 14.92 4 14832 63231 34878864
Cerebellar stroke 14.95 14.92 5 14831 217 34941878
Blepharospasm 14.94 14.92 8 14828 1130 34940965

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic reaction 361.90 12.31 276 28954 83467 79631691
Anaphylactic shock 335.86 12.31 192 29038 35804 79679354
Type IV hypersensitivity reaction 243.94 12.31 81 29149 4000 79711158
Macular oedema 231.81 12.31 84 29146 5390 79709768
Retinal detachment 195.60 12.31 86 29144 9161 79705997
Corneal oedema 156.57 12.31 52 29178 2568 79712590
Rash maculo-papular 139.87 12.31 135 29095 55943 79659215
Drug reaction with eosinophilia and systemic symptoms 136.93 12.31 142 29088 64102 79651056
Retinal toxicity 130.14 12.31 39 29191 1372 79713786
Bronchospasm 118.52 12.31 87 29143 24772 79690386
Retinal oedema 117.05 12.31 33 29197 932 79714226
Retinal infarction 108.62 12.31 23 29207 183 79714975
Endophthalmitis 108.21 12.31 51 29179 6377 79708781
Lung consolidation 106.24 12.31 56 29174 8891 79706267
Resuscitation 98.46 12.31 36 29194 2368 79712790
Anterior chamber inflammation 89.90 12.31 24 29206 550 79714608
Clostridium difficile infection 86.73 12.31 92 29138 42593 79672565
Corneal opacity 84.68 12.31 26 29204 994 79714164
Soft tissue mass 82.74 12.31 27 29203 1261 79713897
Visual acuity reduced 77.35 12.31 73 29157 29396 79685762
Multimorbidity 75.88 12.31 26 29204 1413 79713745
Ocular toxicity 75.45 12.31 23 29207 858 79714300
Oesophageal perforation 73.65 12.31 26 29204 1545 79713613
Kounis syndrome 69.10 12.31 33 29197 4249 79710909
Spinal muscular atrophy 68.60 12.31 18 29212 385 79714773
Type I hypersensitivity 68.26 12.31 33 29197 4365 79710793
Macular detachment 68.23 12.31 16 29214 211 79714947
Clostridium difficile colitis 66.32 12.31 70 29160 32213 79682945
Exposure during pregnancy 61.72 12.31 123 29107 101009 79614149
Toxic epidermal necrolysis 60.32 12.31 78 29152 44503 79670655
Joint swelling 59.72 12.31 16 29214 288630 79426528
Tachypnoea 59.69 12.31 66 29164 31997 79683161
Stoma closure 58.41 12.31 15 29215 294 79714864
Cross sensitivity reaction 58.05 12.31 28 29202 3684 79711474
Accidental overdose 57.91 12.31 72 29158 39509 79675649
Pneumococcal sepsis 57.52 12.31 22 29208 1640 79713518
Corneal deposits 55.76 12.31 16 29214 482 79714676
Pyrexia 53.55 12.31 428 28802 678281 79036877
Circulatory collapse 52.68 12.31 67 29163 37601 79677557
Transplant failure 52.14 12.31 28 29202 4613 79710545
Superinfection 50.70 12.31 28 29202 4874 79710284
Infusion related reaction 49.08 12.31 12 29218 230225 79484933
Pathogen resistance 48.49 12.31 41 29189 14301 79700857
Multiple organ dysfunction syndrome 48.45 12.31 124 29106 120122 79595036
Motor neurone disease 48.37 12.31 15 29215 593 79714565
Arthropathy 47.16 12.31 5 29225 177106 79538052
Cystoid macular oedema 47.06 12.31 20 29210 1960 79713198
Fatigue 46.34 12.31 180 29050 929547 78785611
Rheumatoid arthritis 46.15 12.31 10 29220 208460 79506698
Weight increased 46.11 12.31 22 29208 277364 79437794
Rales 45.84 12.31 46 29184 19955 79695203
Pseudomembranous colitis 45.66 12.31 27 29203 5347 79709811
Inflammatory marker increased 43.26 12.31 34 29196 10706 79704452
Maculopathy 43.25 12.31 21 29209 2804 79712354
Urticaria 42.66 12.31 157 29073 185044 79530114
Renal injury 42.65 12.31 41 29189 16886 79698272
Alopecia 42.20 12.31 16 29214 231339 79483819
Dysbiosis 41.70 12.31 16 29214 1203 79713955
Anticoagulation drug level above therapeutic 41.12 12.31 22 29208 3598 79711560
Nosocomial infection 40.21 12.31 20 29210 2812 79712346
Drug abuse 39.90 12.31 6 29224 162685 79552473
Cataract operation complication 39.74 12.31 11 29219 290 79714868
Respiratory tract infection bacterial 39.70 12.31 18 29212 2059 79713099
Pneumonia 38.97 12.31 391 28839 659855 79055303
Angioedema 38.83 12.31 86 29144 75949 79639209
Pneumonia mycoplasmal 38.71 12.31 16 29214 1462 79713696
Premature rupture of membranes 38.71 12.31 22 29208 4047 79711111
Blood pressure decreased 38.44 12.31 101 29129 99365 79615793
Drug interaction 38.39 12.31 272 28958 414911 79300247
Premature delivery 38.09 12.31 45 29185 23422 79691736
Lower respiratory tract infection bacterial 37.98 12.31 14 29216 942 79714216
Lymphadenectomy 37.69 12.31 15 29215 1244 79713914
Parophthalmia 36.73 12.31 11 29219 386 79714772
Myocardial ischaemia 36.65 12.31 46 29184 25473 79689685
Bronchial disorder 36.60 12.31 18 29212 2471 79712687
Arthralgia 36.55 12.31 99 29131 571704 79143454
Ischaemic cerebral infarction 36.28 12.31 18 29212 2517 79712641
Fall 36.23 12.31 78 29152 487551 79227607
Oesophageal carcinoma 36.07 12.31 31 29199 11053 79704105
Musculoskeletal stiffness 35.61 12.31 10 29220 174998 79540160
Death 35.52 12.31 99 29131 566415 79148743
Anterior chamber fibrin 35.51 12.31 9 29221 167 79714991
Intestinal intraepithelial lymphocytes increased 35.31 12.31 9 29221 171 79714987
Increased bronchial secretion 34.40 12.31 19 29211 3308 79711850
Airway peak pressure increased 33.80 12.31 10 29220 336 79714822
Retinal disorder 33.71 12.31 16 29214 2031 79713127
Pulmonary vasculitis 33.42 12.31 12 29218 749 79714409
Stevens-Johnson syndrome 33.26 12.31 55 29175 39111 79676047
Intestinal ischaemia 33.16 12.31 32 29198 13238 79701920
Face oedema 33.12 12.31 46 29184 28090 79687068
Immunosuppressant drug level increased 33.00 12.31 27 29203 9000 79706158
Shock 32.83 12.31 58 29172 43490 79671668
Erythema 31.95 12.31 164 29066 223126 79492032
Fibrinolysis increased 31.44 12.31 6 29224 26 79715132
Probiotic therapy 31.39 12.31 8 29222 152 79715006
Brain injury 31.12 12.31 29 29201 11488 79703670
Sputum increased 31.11 12.31 20 29210 4593 79710565
Cryptitis 30.81 12.31 9 29221 289 79714869
Sepsis 30.64 12.31 186 29044 269242 79445916
Trimethylaminuria 29.78 12.31 8 29222 188 79714970
Chest X-ray abnormal 29.71 12.31 24 29206 7859 79707299
Eye inflammation 29.56 12.31 22 29208 6391 79708767
Pain 29.08 12.31 146 29084 703656 79011502
Fear 29.01 12.31 38 29192 21948 79693210
Therapeutic product effect decreased 28.78 12.31 12 29218 163851 79551307
Microvillous inclusion disease 28.68 12.31 8 29222 217 79714941
Metabolic disorder 28.53 12.31 25 29205 9145 79706013
Systemic lupus erythematosus 28.51 12.31 5 29225 121144 79594014
Lack of spontaneous speech 28.37 12.31 8 29222 226 79714932
Drug intolerance 28.37 12.31 33 29197 264086 79451072
Vulval cancer metastatic 27.65 12.31 4 29226 0 79715158
Treatment failure 27.59 12.31 14 29216 170472 79544686
Disease complication 27.49 12.31 19 29211 4918 79710240
Meningitis candida 27.27 12.31 7 29223 137 79715021
Cardiac massage 26.72 12.31 5 29225 19 79715139
Cutaneous vasculitis 26.69 12.31 23 29207 8229 79706929
Apoptosis 25.89 12.31 9 29221 511 79714647
Hypersensitivity vasculitis 25.87 12.31 21 29209 6922 79708236
Joint hyperextension 25.63 12.31 8 29222 323 79714835
Pericarditis 25.20 12.31 4 29226 104232 79610926
Renal failure 24.94 12.31 142 29088 200826 79514332
Boutonneuse fever 24.88 12.31 4 29226 4 79715154
Gait disturbance 24.42 12.31 24 29206 207482 79507676
Injury 24.34 12.31 73 29157 77423 79637735
Toxic skin eruption 24.10 12.31 35 29195 22258 79692900
Intentional product use issue 23.86 12.31 13 29217 152099 79563059
Haemoptysis 23.85 12.31 59 29171 55940 79659218
Neuritis 23.74 12.31 12 29218 1746 79713412
Serratia infection 23.62 12.31 12 29218 1764 79713394
Vitreous disorder 23.15 12.31 7 29223 254 79714904
Bulimia nervosa 23.12 12.31 7 29223 255 79714903
Serous retinal detachment 23.11 12.31 10 29220 1024 79714134
Tachycardia 22.98 12.31 127 29103 177641 79537517
Nephritis allergic 22.91 12.31 9 29221 721 79714437
Cardiovascular insufficiency 22.80 12.31 14 29216 2967 79712191
Oliguria 22.78 12.31 29 29201 16280 79698878
Ascites 22.63 12.31 70 29160 75492 79639666
Biopsy 22.63 12.31 9 29221 745 79714413
Pain in extremity 22.59 12.31 64 29166 364474 79350684
Labelled drug-drug interaction medication error 22.37 12.31 38 29192 27612 79687546
Abdominal discomfort 22.22 12.31 36 29194 250691 79464467
Escherichia infection 22.02 12.31 30 29200 17987 79697171
Renal graft infection 21.65 12.31 8 29222 542 79714616
Acute generalised exanthematous pustulosis 21.50 12.31 29 29201 17225 79697933
Toxoplasmosis 21.49 12.31 13 29217 2684 79712474
Endotracheal intubation 21.39 12.31 16 29214 4681 79710477
Venous thrombosis 21.34 12.31 19 29211 7097 79708061
Atheroembolism 21.24 12.31 7 29223 337 79714821
Platelet count decreased 21.24 12.31 24 29206 194640 79520518
Contraindicated product administered 21.24 12.31 16 29214 157522 79557636
Exophthalmos 21.02 12.31 11 29219 1719 79713439
Cardiac arrest 20.95 12.31 121 29109 171975 79543183
Oesophageal spasm 20.91 12.31 14 29216 3442 79711716
Retinal haemorrhage 20.88 12.31 20 29210 8197 79706961
Antidiuretic hormone abnormality 20.72 12.31 5 29225 75 79715083
Aspergillus infection 20.59 12.31 30 29200 19131 79696027
Lip swelling 20.57 12.31 46 29184 40865 79674293
Injection site pain 20.50 12.31 11 29219 129827 79585331
Nasopharyngitis 20.19 12.31 39 29191 253842 79461316
Insomnia 20.08 12.31 37 29193 245133 79470025
Anhedonia 20.04 12.31 26 29204 14872 79700286
Toxicity to various agents 20.02 12.31 83 29147 421457 79293701
Delayed delivery 20.02 12.31 4 29226 23 79715135
Vanishing twin syndrome 19.98 12.31 5 29225 88 79715070
Optic atrophy 19.88 12.31 11 29219 1922 79713236
Sepsis syndrome 19.45 12.31 10 29220 1507 79713651
Transaminases increased 19.43 12.31 52 29178 51691 79663467
Demyelination 19.40 12.31 19 29211 8004 79707154
Delivery 19.33 12.31 8 29222 734 79714424
Rotavirus infection 19.33 12.31 8 29222 734 79714424
Discomfort 19.32 12.31 11 29219 125606 79589552
Macular ischaemia 19.28 12.31 5 29225 102 79715056
Hypopyon 19.03 12.31 9 29221 1133 79714025
Wrong technique in product usage process 19.02 12.31 65 29165 73810 79641348
Intraocular pressure increased 18.97 12.31 20 29210 9185 79705973
Conjunctival oedema 18.91 12.31 9 29221 1149 79714009
Clostridium test positive 18.90 12.31 17 29213 6437 79708721
Rash 18.83 12.31 307 28923 578051 79137107
Skin test positive 18.80 12.31 9 29221 1165 79713993
Toxic anterior segment syndrome 18.68 12.31 12 29218 2752 79712406
Acinetobacter infection 18.63 12.31 12 29218 2765 79712393
Blood cholesterol increased 18.55 12.31 4 29226 83716 79631442
Drug resistance 18.53 12.31 45 29185 42168 79672990
Oesophageal pain 18.22 12.31 14 29216 4265 79710893
Tubulointerstitial nephritis 18.13 12.31 42 29188 38193 79676965
Emotional distress 17.96 12.31 43 29187 39926 79675232
Acute hepatic failure 17.61 12.31 36 29194 30077 79685081
Drug hypersensitivity 17.54 12.31 177 29053 298739 79416419
Product preparation issue 17.23 12.31 9 29221 1401 79713757
Cardiomegaly 17.21 12.31 33 29197 26319 79688839
Retinopathy 17.16 12.31 13 29217 3878 79711280
Hypotension 17.13 12.31 241 28989 440076 79275082
Pruritus 16.99 12.31 220 29010 394428 79320730
Intentional product misuse 16.65 12.31 7 29223 95158 79620000
Mediastinal effusion 16.58 12.31 4 29226 60 79715098
Natural killer cell count decreased 16.58 12.31 4 29226 60 79715098
Arteriospasm coronary 16.41 12.31 16 29214 6700 79708458
Mechanical ventilation 16.25 12.31 11 29219 2753 79712405
Cardiopulmonary failure 16.24 12.31 16 29214 6785 79708373
Deafness bilateral 16.05 12.31 10 29220 2175 79712983
Klebsiella infection 16.01 12.31 24 29206 15696 79699462
Hepatosplenomegaly 15.86 12.31 15 29215 6054 79709104
Hypertension 15.81 12.31 65 29165 330927 79384231
Bronchopneumopathy 15.56 12.31 7 29223 786 79714372
Visual impairment 15.55 12.31 71 29159 92060 79623098
Renal impairment 15.49 12.31 105 29125 157678 79557480
Live birth 15.48 12.31 26 29204 18718 79696440
Hydronephrosis 15.48 12.31 25 29205 17429 79697729
Wound 15.40 12.31 12 29218 116167 79598991
Coma blister 15.27 12.31 5 29225 236 79714922
Drug-induced liver injury 15.16 12.31 56 29174 66061 79649097
Haemorrhoids thrombosed 15.03 12.31 5 29225 248 79714910
Linear IgA disease 15.01 12.31 11 29219 3121 79712037
White blood cell count decreased 14.90 12.31 29 29201 188259 79526899
Pneumonectomy 14.89 12.31 4 29226 94 79715064
Acute pulmonary oedema 14.89 12.31 22 29208 14208 79700950
Atelectasis 14.82 12.31 35 29195 32222 79682936
Systemic infection 14.68 12.31 18 29212 9734 79705424
Leukocytosis 14.66 12.31 42 29188 43413 79671745
Cyanosis 14.60 12.31 30 29200 25152 79690006
Dyspnoea 14.59 12.31 414 28816 856611 78858547
Bladder neck obstruction 14.47 12.31 4 29226 105 79715053
Genitourinary tract infection 14.45 12.31 5 29225 280 79714878
Lymphangitis 14.44 12.31 8 29222 1400 79713758
Blindness 14.37 12.31 32 29198 28351 79686807
Product monitoring error 14.32 12.31 17 29213 8889 79706269
Headache 14.31 12.31 162 29068 653610 79061548
Motor dysfunction 14.31 12.31 22 29208 14711 79700447
Pneumococcal infection 14.30 12.31 7 29223 951 79714207
Pneumonia klebsiella 14.18 12.31 13 29217 5041 79710117
Brain compression 14.18 12.31 6 29224 582 79714576
Urticaria contact 14.04 12.31 3 29227 25 79715133
Anti factor V antibody positive 14.04 12.31 3 29227 25 79715133
Inappropriate schedule of product administration 14.01 12.31 17 29213 133611 79581547
Blood pressure increased 13.91 12.31 36 29194 211324 79503834
Weight decreased 13.88 12.31 75 29155 355123 79360035
Blood glucose increased 13.87 12.31 13 29217 114962 79600196
Erosive duodenitis 13.84 12.31 9 29221 2108 79713050
Neuropathy peripheral 13.76 12.31 19 29211 141286 79573872
Moraxella infection 13.71 12.31 6 29224 631 79714527
HER2 positive breast cancer 13.61 12.31 5 29225 333 79714825
Eosinophilia 13.57 12.31 42 29188 45303 79669855
Fluid intake reduced 13.56 12.31 14 29216 6274 79708884
Cholestasis 13.54 12.31 46 29184 52063 79663095
Contusion 13.51 12.31 21 29209 148755 79566403
Anaphylactoid reaction 13.41 12.31 13 29217 5409 79709749
Rash erythematous 13.30 12.31 49 29181 57720 79657438
Scoliosis 13.26 12.31 15 29215 7449 79707709
B-lymphocyte count increased 13.18 12.31 4 29226 147 79715011
Mucosal erosion 13.09 12.31 9 29221 2309 79712849
Drug level increased 13.07 12.31 38 29192 39613 79675545
Respiratory failure 13.05 12.31 112 29118 180799 79534359
Amaurosis 12.86 12.31 7 29223 1184 79713974
Peripheral swelling 12.84 12.31 53 29177 269564 79445594
Cerebral ischaemia 12.72 12.31 18 29212 11177 79703981
Cholestatic liver injury 12.51 12.31 12 29218 4929 79710229
Decreased appetite 12.46 12.31 74 29156 342344 79372814
Pupillary block 12.37 12.31 3 29227 46 79715112

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01DC02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Second-generation cephalosporins
ATC J01RA03 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
COMBINATIONS OF ANTIBACTERIALS
Combinations of antibacterials
ATC S01AA27 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIINFECTIVES
Antibiotics
FDA CS M0003827 Cephalosporins
FDA EPC N0000175488 Cephalosporin Antibacterial
CHEBI has role CHEBI:88188 allergenic drug
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Acute otitis media indication 3110003
Streptococcal meningitis indication 4510004 DOID:11574
Septicemia due to Escherichia coli indication 9323009
Bacterial septicemia indication 10001005 DOID:0040085
Staphylococcal meningitis indication 12166008
Gonorrhea indication 15628003 DOID:7551
Haemophilus Influenzae Acute Otitis Media indication 19021002
Infection of skin AND/OR subcutaneous tissue indication 19824006
Acute gonococcal cervicitis indication 20943002 DOID:10615
Staphylococcal pneumonia indication 22754005
Lyme disease indication 23502006 DOID:11729
Streptococcal septicemia indication 29577008
Acute gonococcal urethritis indication 29864006
Pneumonia due to Streptococcus indication 34020007
Streptococcal tonsillitis indication 41582007
Gonorrhea of rectum indication 42746002
Impetigo indication 48277006 DOID:8504
Lower respiratory tract infection indication 50417007
Pneumonia due to Escherichia coli indication 51530003
Bacterial pneumonia indication 53084003 DOID:874
Klebsiella cystitis indication 60867007
Acute gonococcal endometritis indication 65295003 DOID:7527
Acute maxillary sinusitis indication 68272006 DOID:2050
Haemophilus influenzae pneumonia indication 70036007
Infection due to Escherichia coli indication 71057007
Rhinoscleroma indication 72409005 DOID:11336
Gonorrhea of pharynx indication 74372003
Acute bacterial sinusitis indication 75498004
Bacterial meningitis indication 95883001 DOID:9470
Infection of bone indication 111253001
Staphylococcal septicemia indication 111821004
Infection due to Enterobacteriaceae indication 128945009
Bacterial infection due to Klebsiella pneumoniae indication 186435004
Escherichia coli urinary tract infection indication 301011002
Streptococcus pyogenes infection indication 302809008
Bacterial urinary infection indication 312124009
Infective otitis media indication 312218008
Infectious disorder of joint indication 363162000
Infection due to Staphylococcus aureus indication 406602003
Acute exacerbation of chronic bronchitis indication 425748003
Osteomyelitis due to Staphylococcus aureus indication 428783003
Moraxella Catarrhalis Acute Otitis Media indication 703469002
Haemophilus Influenzae Bronchitis indication
Streptococcus Pneumoniae Chronic Bronchitis indication
Disseminated Gonococcal Infection indication
Streptococcus Pneumoniae Bronchitis indication
Haemophilus Parainfluenzae Bronchitis indication
Staphylococcus Aureus Joint Infection indication
H. Influenzae Meningitis indication
Prevention of Perioperative Infection indication
Haemophilus Influenzae Chronic Bronchitis indication
Haemophilus Septicemia indication
Haemophilus Parainfluenzae Chronic Bronchitis indication
Open Heart Surgery Infection Prevention indication
Pyrexia of unknown origin off-label use 7520000
Sepsis of the newborn off-label use 206376005
Neonatal pneumonia off-label use 233619008
Neonatal meningitis off-label use 276674008
Blood coagulation disorder contraindication 64779008 DOID:1247
Factor II deficiency contraindication 73975000
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409
Pseudomembranous enterocolitis contraindication 397683000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.32 acidic
pKa2 13.33 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Carbonic anhydrase 2 Enzyme IC50 5.92 WOMBAT-PK
72 kDa type IV collagenase Enzyme IC50 4.37 WOMBAT-PK
Matrix metalloproteinase-9 Enzyme IC50 4.96 WOMBAT-PK
Bacterial penicillin-binding protein Enzyme INHIBITOR CHEMBL CHEMBL
Penicillin-binding protein 1A Enzyme WOMBAT-PK

External reference:

IDSource
4019668 VUID
N0000147760 NUI
D00262 KEGG_DRUG
56238-63-2 SECONDARY_CAS_RN
204144 RXNORM
C0007562 UMLSCUI
CHEBI:3515 CHEBI
KOV PDB_CHEM_ID
CHEMBL2146124 ChEMBL_ID
CHEMBL1436 ChEMBL_ID
D002444 MESH_DESCRIPTOR_UI
DB01112 DRUGBANK_ID
5479529 PUBCHEM_CID
10900 IUPHAR_LIGAND_ID
3902 INN_ID
O1R9FJ93ED UNII
2973 MMSL
4389 MMSL
d00056 MMSL
002731 NDDF
003590 NDDF
372833007 SNOMEDCT_US
48753004 SNOMEDCT_US
73986003 SNOMEDCT_US
4017551 VANDF
4019668 VANDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cefuroxime HUMAN PRESCRIPTION DRUG LABEL 1 0143-9567 INJECTION, POWDER, FOR SOLUTION 1.50 g INTRAVENOUS ANDA 23 sections
Cefuroxime HUMAN PRESCRIPTION DRUG LABEL 1 0143-9567 INJECTION, POWDER, FOR SOLUTION 1.50 g INTRAVENOUS ANDA 23 sections
Cefuroxime HUMAN PRESCRIPTION DRUG LABEL 1 0143-9568 INJECTION, POWDER, FOR SOLUTION 750 mg INTRAMUSCULAR ANDA 23 sections
Cefuroxime HUMAN PRESCRIPTION DRUG LABEL 1 0143-9568 INJECTION, POWDER, FOR SOLUTION 750 mg INTRAMUSCULAR ANDA 23 sections
Cefuroxime HUMAN PRESCRIPTION DRUG LABEL 1 0143-9569 INJECTION, POWDER, FOR SOLUTION 7.50 g INTRAVENOUS ANDA 24 sections
Cefuroxime HUMAN PRESCRIPTION DRUG LABEL 1 0143-9976 INJECTION, POWDER, FOR SOLUTION 750 mg INTRAVENOUS ANDA 24 sections
Cefuroxime HUMAN PRESCRIPTION DRUG LABEL 1 0143-9976 INJECTION, POWDER, FOR SOLUTION 750 mg INTRAVENOUS ANDA 24 sections
Cefuroxime HUMAN PRESCRIPTION DRUG LABEL 1 0143-9977 INJECTION, POWDER, FOR SOLUTION 1.50 g INTRAVENOUS ANDA 22 sections
Cefuroxime HUMAN PRESCRIPTION DRUG LABEL 1 0143-9977 INJECTION, POWDER, FOR SOLUTION 1.50 g INTRAVENOUS ANDA 22 sections
Cefuroxime HUMAN PRESCRIPTION DRUG LABEL 1 0143-9979 INJECTION, POWDER, FOR SOLUTION 750 mg INTRAMUSCULAR ANDA 22 sections
Cefuroxime HUMAN PRESCRIPTION DRUG LABEL 1 0143-9979 INJECTION, POWDER, FOR SOLUTION 750 mg INTRAMUSCULAR ANDA 22 sections
Cefuroxime and Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0264-3112 INJECTION, SOLUTION 750 mg INTRAVENOUS NDA 24 sections
Cefuroxime and Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0264-3114 INJECTION, SOLUTION 1.50 g INTRAVENOUS NDA 24 sections
Cefuroxime sodium HUMAN PRESCRIPTION DRUG LABEL 1 25021-118 INJECTION, POWDER, FOR SOLUTION 750 mg INTRAVENOUS ANDA 25 sections
Cefuroxime sodium HUMAN PRESCRIPTION DRUG LABEL 1 25021-119 INJECTION, POWDER, FOR SOLUTION 1.50 g INTRAVENOUS ANDA 25 sections
Cefuroxime sodium HUMAN PRESCRIPTION DRUG LABEL 1 25021-182 INJECTION, POWDER, FOR SOLUTION 750 mg INTRAVENOUS ANDA 26 sections
Cefuroxime sodium HUMAN PRESCRIPTION DRUG LABEL 1 25021-183 INJECTION, POWDER, FOR SOLUTION 1.50 g INTRAVENOUS ANDA 26 sections
Cefuroxime HUMAN PRESCRIPTION DRUG LABEL 1 44567-710 INJECTION, POWDER, FOR SOLUTION 750 mg INTRAMUSCULAR ANDA 24 sections
Cefuroxime HUMAN PRESCRIPTION DRUG LABEL 1 44567-711 INJECTION, POWDER, FOR SOLUTION 1.50 g INTRAVENOUS ANDA 24 sections
Cefuroxime HUMAN PRESCRIPTION DRUG LABEL 1 44567-712 INJECTION, POWDER, FOR SOLUTION 7.50 g INTRAVENOUS ANDA 25 sections
Cefuroxime HUMAN PRESCRIPTION DRUG LABEL 1 44567-720 INJECTION, POWDER, FOR SOLUTION 750 mg INTRAVENOUS ANDA 24 sections
Cefuroxime HUMAN PRESCRIPTION DRUG LABEL 1 44567-722 INJECTION, POWDER, FOR SOLUTION 1.50 g INTRAVENOUS ANDA 24 sections